COMP <GO>
CBT vs AVNT // EV/EBITDA & P/E VALUATION
Cabot Corporation (NYSE) VS. Avient Corporation (NYSE) • 15-METRIC TALLY: CBT 7
— AVNT 4
▲ EV/EBITDA & P/E VALUATION LEADER: CBT
LAST: $73.85 (+0.11%) • MKT CAP: $3.81B
valuation
5.2x
LAST: $42.88 (+1.64%) • MKT CAP: $3.93B
valuation
19.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CBT VS. AVNT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CBT | AVNT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.30% | 31.20% | -5.90 | AVNT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.30% | 3.70% | +18.60 | CBT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 5.2x | 19.9x | -14.70 | CBT | /valuation <GO> |
| Free Cash Flow Yield | 10.25% | 4.96% | +5.29 | CBT | /fcf-yield <GO> |
| Operating Margin | 16.70% | 6.20% | +10.50 | CBT | /operating-margins <GO> |
| Net Profit Margin | 8.90% | 2.50% | +6.40 | CBT | /net-margins <GO> |
| Revenue Growth (YoY) | -7.00% | 0.60% | -7.60 | AVNT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.52% | 2.51% | +0.01 | CBT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.4 | 63.5 | -20.10 | AVNT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.7x | 44.6x | -33.90 | CBT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.81B | $3.93B | -$120.0M | AVNT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CBT REV | AVNT REV | CBT GROSS % | AVNT GROSS % | CBT FCF | AVNT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $3.26B | 25.3% | 31.2% | $391.0M | $195.0M |
| FY 2024 | $3.99B | $3.24B | 24.0% | 32.6% | $451.0M | $134.9M |
| FY 2023 | $3.93B | $3.14B | — | — | $595.0M | $201.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CBT // BETA —
AVNT // BETA —